BS-mAb31

Analysis of the GRADUATE I/II trials identifies risk factors for ARIA-E in gantenerumab-treated Alzheimer's patients, beyond the known APOE ε4 allele.

Trontinemab, a Roche drug, uses a 'Brainshuttle' to cross the blood-brain barrier, potentially reducing brain swelling and bleeding compared to existing treatments.

The European Medicines Agency (EMA) has recommended Leqembi for treating early-stage Alzheimer's, reversing its initial rejection due to brain swelling risks.

Trontinemab, a transferrin receptor-based antibody, rapidly clears amyloid plaques in Alzheimer's patients with few mild ARIA cases in early trials.

Trontinemab effectively clears amyloid plaques from the brain, showing promise in Alzheimer's disease treatment.